Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease.
The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
Questions:
- Opicapone has been investigated in randomized clinical trials, can you please summarize the mode of action of Opicapone and the trial findings?
- It is valuable to complement trial data with clinical experience in the real world – what did the OPTIPARK study investigate and what were the key findings?
- How do you see these real-world data contributing to the use of Opicapone alongside levodopa-based drugs in routine practice for the management of Parkinson’s disease?
Disclosures: Professor Heinz Reichmann was acting on Advisory Boards and gave lectures and received research grants within the last 5 years from Bial, Desitin, Eisai, Kyowa-Kirin, Merz, Novartis, UCB Pharma and Zambon.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021
